KRTX Karuna Therapeutics Inc.

109.3
+4.78  (+5%)
Previous Close 104.52
Open 102.5
Price To Book 17.49
Market Cap 2,843,194,012
Shares 26,012,754
Volume 941,601
Short Ratio
Av. Daily Volume 969,830
Stock charts supplied by TradingView

NewsSee all news

  1. Karuna Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  2. Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  3. Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  4. Karuna Therapeutics Announces Proposed Public Offering of Common Stock

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  5. Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

    KarXT Demonstrated Statistically Significant and Clinically Meaningful Improvement in Total PANSS Score at All Time Points Over Five Weeks and was Well-Tolerated Compared to Placebo Improvement in Total PANSS Score at

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data met primary endpoint - November 18, 2019.
KarXT
Acute psychosis in patients with schizophrenia
Phase 1b trial to commence 1H 2020.
KarXT
Schizophrenia - cognitive symptoms
Phase 1b trial to commence 1H 2020.
KarXT
Schizophrenia - negative symptoms
Phase 1b trial to commence 4Q 2019.
KarXT
Alzheimer’s disease

Latest News

  1. Karuna Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  2. Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  3. Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  4. Karuna Therapeutics Announces Proposed Public Offering of Common Stock

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  5. Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

    KarXT Demonstrated Statistically Significant and Clinically Meaningful Improvement in Total PANSS Score at All Time Points Over Five Weeks and was Well-Tolerated Compared to Placebo Improvement in Total PANSS Score at

  6. Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia

    Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal

  7. Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update

    Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019 Phase 1b clinical trials for the treatment of psychosis in